Huntington’s Disease Treatment Market
Huntington’s Disease Treatment Market Analysis, By Treatment (Symptomatic Treatment of Huntington’s disease, Disease-Modifying Therapies for Huntington’s disease), and By Region - Global Market Insights 2022-2032
Analysis of Huntington's Disease Treatment market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Huntington’s disease Treatment Market Outlook (2022-2032)
The global Huntington’s disease treatment market was estimated to have a market size worth US$ 360 Million in 2021 and is expected to grow at a CAGR of 20% from 2022-2032.
The market is estimated to reach US$ 2.7 Billion by the end of 2032.
The Huntington’s disease (HD) Treatment Market is expected to grow during the forecast period, reaching a global market size of US$ 432 Mn by the end of 2022.
Huntington’s disease affects approximately 31,000 people in North America, with a prevalence of 5.8 per 100,000 people. Ingrezza's expected label expansion to include chorea associated with Huntington's disease, together with the high incidence of Huntington’s disease in western countries, is anticipated to be major market drivers.
The prevalence of Huntington’s disease in children is much lower, with around 5.1% to 10% of all cases. The prevalence of HD in Europe is ten in 100,000
Report Attributes |
Details |
|
Market Size in 2021 |
US$ 360 Million |
|
Market Size in 2022 |
US$ 432 Million |
|
Forecasted Market Value in 2032 |
US$ 2.7 Billion |
|
CAGR during the forecast period, 2022-2032 |
20% |
|
Market Share North America Expected During 2022 |
77% |
|
Key Players Offering Treatment for Huntington’s Disease |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Demand Analysis of Huntington’s Disease Treatment, 2015-2021 vs. Market Outlook 2022-2032
The global market for Huntington’s disease treatment expanded at a compound annual growth rate of 15.6% between 2015 and 2021, according to market research and competitive intelligence provider Fact.MR.
North-America was the dominant regional market during this time and held a significant share of global demand.
The market witnessed a slow growth rate of 7% from 2019 to the middle of 2020 due to the global COVID-19 pandemic. During the COVID-19 pandemic, online pharmacies were selling off-label drugs to manage symptoms associated with HD, such as antipsychotics, antidepressants, and anticonvulsants. Clinical trials were delayed during the COVID-19 pandemic due to the government-imposed blackout.
From 2022 and 2023, the market is forecast to grow at a y-o-y rate of 6.5%. According to most hospitals and clinics worldwide, the frequency of clinical visits for the diagnosis and treatment of HD has increased post the second quarter of 2021.
Because of this, the market will continue to grow with the expected growth rate beyond COVID-19. In the aftermath of the pandemic, clinical trials to develop a treatment for Huntington's disease have increased.
What are the specific drivers of the Huntington’s disease Treatment Market?
Growing Adoption of Improved Medical Treatments and Therapies to Drive Demand for Effective Treatments
Market growth is expected to be driven by the involvement of major market players in research for a cure for Huntington's disease (HD). There is a growing patient population and prevalence of diseases worldwide, mainly in North America and Europe. There will be further positive contribution to the market growth from the lack of disease-modifying drugs and other treatment methods available to HD patients.
As a potentially effective treatment for HD, stem cell therapy is generating interest. The ADORE-DH phase 2/ 3 trial uses CELLAVITA-HD, stem cell therapy being developed by Cellavita in collaboration with AzidusPharma. Additionally, alternative therapy options, such as speech therapy, psychological treatment, and physiotherapy, had a positive impact on the market growth for Huntington's disease treatment market.
Growing R&D Activities to accelerate the Market Growth
Research and development of Huntington's disease treatment methods continues to be made easier by the lack of a proper treatment or medication for the disease. This is expected to boost market growth significantly over the forecast period. Furthermore, government initiatives that encourage the development of new drugs are an important driver of the market's growth.
Global Huntington's disease treatment market is expected to grow due to increasing prevalence of disease and increased R&D activities by institutes and universities during the forecast period. The Huntington's disease Society of America estimates that there are approximately 30,000 symptomatic Americans and more than 200,000 people at risk for inheriting the disease.
Annexon Inc., for example, is developing ANX005-an experimental monoclonal antibody that addresses abnormal C1q activity in certain complement-mediated neurodegenerative diseases, such as Huntington's disease. In this innovative medication, C1q is suppressed along with the classical complement system, and it is administered intravenously (IV). The company started a phase 2 clinical trial of ANX005 in November 2020 to treat HD patients.
Failed therapies can be a significant threat to this market
The development of HD-specific therapies has been plagued by significant obstacles as several therapies have either failed to demonstrate efficacy or caused dangerous side effects. The Phase III trial GENERATION HD1 showed tominersen did not improve the symptoms of manifest HD, as F Hoffmann-La Roche Ltd discontinued the study in March 2021.
Data from phase III research has been analyzed by an unblinded Independent Data Monitoring Committee (iDMC) based on preliminary findings from that research. Upon analyzing these data, there was no indication of new or evolving safety signals for Tominersen.
The COVID-19 pandemic has had a slight negative impact on the market for Huntington's disease treatments. Clinical trials may be delayed due to the pandemic, which can delay the entry of pipeline candidates into the market.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise-Analysis
How will the growth emerge in the North American region during the forecast period?
Various measures towards preventing HD will drive this growth
In 2022, the North American market is expected to account for 77% of global revenue for Huntington's disease treatments. The increase in awareness and sales of Huntington's disease treatment products are a result of the high prevalence of Huntington's disease, the increased healthcare expenditure, technological advances, and proactive government initiatives.
Some of the major players in the market, including H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd., have introduced symptom management products to support market growth.
What will be the market outlook in the APAC region?
Increasing product penetration will account for steady growth
Due to increasing product penetration, potential for growth, and growth in the prevalence of Huntington's disease in developing countries, the Asia Pacific market for Huntington's disease treatment is expected to grow rapidly over the forecast period with a projected 45% of the total revenue in this market.
As governments take more initiatives to improve the health status of the population, the market in the region is expected to grow.
Category-wise Insights
What can be expected from the Symptomatic Treatment Segment during the forecast period?
Huntington's disease treatment is expected to dominate the market during the forecast period, with symptomatic treatment to account for 98% of market revenue in 2022.
The growth of this market is attributable to several symptom management products and their patent protection. First-line therapy for Huntington's chorea consists of xenazine and austedo. R&D of potential Huntington's disease product candidates may contribute to the growth of this segment.
In October 2021, SOM BIOTECH's drug SOM3355 was designated an orphan drug by the US Food and Drug Administration for the treatment of chorea associated with Huntington's disease.This is for use in the treatment of chorea associated with Huntington's disease. As a result, the product will be exclusively available in the U.S. after approval by the FDA.
Why is the disease-modifying therapies segment gaining preference?
Advanced therapies will drive this market
The disease-modifying therapies segment is expected to grow at the fastest rate over the forecast period. An increasing demand for advanced products, such as gene therapy and stem cell therapy, along with an increase in research and development for disease-modifying therapy are responsible for this growth.
The government's Fast Track Designation program by the US FDA could lead to accelerated registration processes, fueling the market in the years to come.
As an example, the US Food and Drug Administration granted fast track designation in September 2021 to Sage Therapeutics's candidate drug, SAGE-718, as a potential treatment for Huntington's disease. IQVIA predicts significant growth in US sales of tetrabenazine tablets 12.5 mg and 25 mg in the forecast period of 2022- 2032.
The disease-modifying therapies segment was valued at US$ 4.2 Bn in 2021 and is projected to reach US$ 9.83 Bn by 2032, growing at a CAGR of 9.1%.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Several key players are adopting various strategies to gain a larger share of the market, including new product development and partnerships.
- Spark Therapeutics, Inc. (a subsidiary of F. Hoffmann La Roche Ltd.) formed a partnership with NeuExcell Therapeutics Inc for the development of gene therapy for treating HD patients in September 2021. NeuExcell Therapeutics will receive upfront license fees, R&D milestone payments, and product royalties up to approximately USD 190 million as part of the agreement.
- Austedo, a drug intended to treat chorea associated with HD by Teva Pharmaceutical Industries Ltd, has been approved by the National Medical Products Association (NMPA) in China in May 2020. After the United States, China has approved AUSTEDO. The company expects to expand its patient base and revenue through this geographical expansion.
- As part of its participation in September 2021, Prilenia Therapeutics B.V. announced its participation in the H.C. Walkewright 23rd Annual Global Investment Conference, Cantor Virtual Global Healthcare Conference, and European Huntington Disease Network to present phase 3 results for candidate pridopidine. Healthcare conferences offer a great opportunity to increase the customer base.
Key Segments Covered in the Industry Survey
-
By Treatment
- Symptomatic Treatment of Huntington’s disease
- Disease-Modifying Therapies for Huntington’s disease
-
By Region
- North America
- Latin America
- Europe
- APAC
- MEA
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Summary of Statistics 1.3. Key Market Characteristics & Attributes 1.4. Fact.MR Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Risks and Trends Assessment 3.1. Risk Assessment 3.1.1. COVID-19 Crisis and Impact on Huntington’s Disease Treatment Demand 3.1.2. COVID-19 Impact Benchmark with Previous Crisis 3.1.3. Impact on Market Value (US$ Mn) 3.1.4. Assessment by Key Countries 3.1.5. Assessment by Key Market Segments 3.1.6. Action Points and Recommendation for Suppliers 3.2. Key Trends Impacting the Market 3.3. Formulation and Product Development Trends 4. Market Background and Foundation Data Points 4.1. Global Huntington’s Disease Treatment Market (US$ Mn) 4.2. Huntington’s Disease Treatment Market Opportunity Assessment (US$ Mn) 4.2.1. Total Available Market 4.2.2. Serviceable Addressable Market 4.2.3. Serviceable Obtainable Market 4.3. Market Scenario Forecast 4.3.1. Demand in optimistic Scenario 4.3.2. Demand in Likely Scenario 4.3.3. Demand in Conservative Scenario 4.4. Investment Feasibility Analysis 4.4.1. Investment in Established Markets 4.4.1.1. In Short Term 4.4.1.2. In Long Term 4.4.2. Investment in Emerging Markets 4.4.2.1. In Short Term 4.4.2.2. In Long Term 4.5. Forecast Factors - Relevance & Impact 4.5.1. Top Companies Historical Growth 4.5.2. Global Huntington’s Disease Treatment Market Growth 4.5.3. Huntington’s Disease Treatment Adoption Rate, by Country 4.6. Market Dynamics 4.6.1. Market Driving Factors and Impact Assessment 4.6.2. Prominent Market Challenges and Impact Assessment 4.6.3. Huntington’s Disease Treatment Market Opportunities 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment 5. Key Success Factors 5.1. Manufacturers’ Focus on Low Penetration High Growth Markets 5.2. Banking on with Segments High Incremental Opportunity 5.3. Peer Benchmarking 6. Global Huntington’s Disease Treatment Market Demand Analysis 2015-2021 and Forecast, 2022-2032 6.1. Historical Market Analysis, 2015-2021 6.2. Current and Future Market Projections, 2022-2032 6.3. Y-o-Y Growth Trend Analysis 7. Global Huntington’s Disease Treatment Market Value Analysis 2015-2021 and Forecast, 2022-2032 7.1. Historical Market Value (US$ Mn) Analysis, 2015-2021 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Huntington’s Disease Treatment Market Analysis 2015-2021 and Forecast 2022-2032, By Treatment 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Treatment , 2015-2021 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Treatment , 2022-2032 8.3.1. Symptomatic Treatment 8.3.2. Disease-modifying Therapies 8.4. Market Attractiveness Analysis By Treatment 9. Global Huntington’s Disease Treatment Market Analysis 2015-2021 and Forecast 2022-2032, By Region 9.1. Introduction 9.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2021 9.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2022-2032 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. Asia Pacific 9.3.5. Middle East and Africa (MEA) 9.4. Market Attractiveness Analysis By Region 10. North America Huntington’s Disease Treatment Market Analysis 2015-2021 and Forecast 2022-2032 10.1. Introduction 10.2. Pricing Analysis 10.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 10.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 10.4.1. By Country 10.4.1.1. U.S. 10.4.1.2. Canada 10.4.2. By Treatment 10.5. Market Attractiveness Analysis 10.5.1. By Country 10.5.2. By Treatment 11. Latin America Huntington’s Disease Treatment Market Analysis 2015-2021 and Forecast 2022-2032 11.1. Introduction 11.2. Pricing Analysis 11.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 11.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 11.4.1. By Country 11.4.1.1. Brazil 11.4.1.2. Mexico 11.4.1.3. Rest of Latin America 11.4.2. By Treatment 11.5. Market Attractiveness Analysis 11.5.1. By Country 11.5.2. By Treatment 12. Europe Huntington’s Disease Treatment Market Analysis 2015-2021 and Forecast 2022-2032 12.1. Introduction 12.2. Pricing Analysis 12.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 12.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 12.4.1. By Country 12.4.1.1. Germany 12.4.1.2. France 12.4.1.3. U.K. 12.4.1.4. Italy 12.4.1.5. Benelux 12.4.1.6. Nordic Countries 12.4.1.7. Rest of Europe 12.4.2. By Treatment 12.5. Market Attractiveness Analysis 12.5.1. By Country 12.5.2. By Treatment 13. Asia Pacific Huntington’s Disease Treatment Market Analysis 2015-2021 and Forecast 2022-2032 13.1. Introduction 13.2. Pricing Analysis 13.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 13.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 13.4.1. By Country 13.4.1.1. China 13.4.1.2. Japan 13.4.1.3. South Korea 13.4.1.4. Rest of Asia Pacific 13.4.2. By Treatment 13.5. Market Attractiveness Analysis 13.5.1. By Country 13.5.2. By Treatment 14. Middle East and Africa Huntington’s Disease Treatment Market Analysis 2015-2021 and Forecast 2022-2032 14.1. Introduction 14.2. Pricing Analysis 14.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 14.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032 14.4.1. By Country 14.4.1.1. GCC Countries 14.4.1.2. South Africa 14.4.1.3. Turkey 14.4.1.4. Rest of Middle East and Africa 14.4.2. By Treatment 14.5. Market Attractiveness Analysis 14.5.1. By Country 14.5.2. By Treatment 15. Key Countries Huntington’s Disease Treatment Market Analysis 2015-2021 and Forecast 2022-2032 15.1. Introduction 15.1.1. Market Value Proportion Analysis, By Key Countries 15.1.2. Global Vs. Country Growth Comparison 15.2. US Huntington’s Disease Treatment Market Analysis 15.2.1. Value Proportion Analysis by Market Taxonomy 15.2.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 15.2.2.1. By Treatment 15.3. Canada Huntington’s Disease Treatment Market Analysis 15.3.1. Value Proportion Analysis by Market Taxonomy 15.3.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 15.3.2.1. By Treatment 15.4. Mexico Huntington’s Disease Treatment Market Analysis 15.4.1. Value Proportion Analysis by Market Taxonomy 15.4.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 15.4.2.1. By Treatment 15.5. Brazil Huntington’s Disease Treatment Market Analysis 15.5.1. Value Proportion Analysis by Market Taxonomy 15.5.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 15.5.2.1. By Treatment 15.6. Germany Huntington’s Disease Treatment Market Analysis 15.6.1. Value Proportion Analysis by Market Taxonomy 15.6.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 15.6.2.1. By Treatment 15.7. France Huntington’s Disease Treatment Market Analysis 15.7.1. Value Proportion Analysis by Market Taxonomy 15.7.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 15.7.2.1. By Treatment 15.8. Italy Huntington’s Disease Treatment Market Analysis 15.8.1. Value Proportion Analysis by Market Taxonomy 15.8.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 15.8.2.1. By Treatment 15.9. BENELUX Huntington’s Disease Treatment Market Analysis 15.9.1. Value Proportion Analysis by Market Taxonomy 15.9.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 15.9.2.1. By Treatment 15.10. UK Huntington’s Disease Treatment Market Analysis 15.10.1. Value Proportion Analysis by Market Taxonomy 15.10.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 15.10.2.1. By Treatment 15.11. Nordic Countries Huntington’s Disease Treatment Market Analysis 15.11.1. Value Proportion Analysis by Market Taxonomy 15.11.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 15.11.2.1. By Treatment 15.12. China Huntington’s Disease Treatment Market Analysis 15.12.1. Value Proportion Analysis by Market Taxonomy 15.12.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 15.12.2.1. By Treatment 15.13. Japan Huntington’s Disease Treatment Market Analysis 15.13.1. Value Proportion Analysis by Market Taxonomy 15.13.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 15.13.2.1. By Treatment 15.14. South Korea Huntington’s Disease Treatment Market Analysis 15.14.1. Value Proportion Analysis by Market Taxonomy 15.14.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 15.14.2.1. By Treatment 15.15. GCC Countries Huntington’s Disease Treatment Market Analysis 15.15.1. Value Proportion Analysis by Market Taxonomy 15.15.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 15.15.2.1. By Treatment 15.16. South Africa Huntington’s Disease Treatment Market Analysis 15.16.1. Value Proportion Analysis by Market Taxonomy 15.16.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 15.16.2.1. By Treatment 15.17. Turkey Huntington’s Disease Treatment Market Analysis 15.17.1. Value Proportion Analysis by Market Taxonomy 15.17.2. Value & Analysis and Forecast by Market Taxonomy, 2015-2032 15.17.2.1. By Treatment 15.17.3. Competition Landscape and Player Concentration in the Country 16. Market Structure Analysis 16.1. Market Analysis by Tier of Companies 16.2. Market Concentration 16.3. Market Share Analysis of Top Players 16.4. Market Presence Analysis 16.4.1. By Regional footprint of Players 16.4.2. Product footprint by Players 17. Competition Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Competition Deep Dive 17.3.1. H. Lundbeck A/S 17.3.1.1. Overview 17.3.1.2. Product Portfolio 17.3.1.3. Sales Footprint 17.3.1.4. Strategy Overview 17.3.2. Teva Pharmaceutical Industries Ltd 17.3.2.1. Overview 17.3.2.2. Product Portfolio 17.3.2.3. Sales Footprint 17.3.2.4. Strategy Overview 17.3.3. Bausch Health Companies Inc. 17.3.3.1. Overview 17.3.3.2. Product Portfolio 17.3.3.3. Sales Footprint 17.3.3.4. Strategy Overview 17.3.4. Hetero 17.3.4.1. Overview 17.3.4.2. Product Portfolio 17.3.4.3. Sales Footprint 17.3.4.4. Strategy Overview 17.3.5. Lupin 17.3.5.1. Overview 17.3.5.2. Product Portfolio 17.3.5.3. Sales Footprint 17.3.5.4. Strategy Overview 17.3.6. Hikma Pharmaceuticals PLC 17.3.6.1. Overview 17.3.6.2. Product Portfolio 17.3.6.3. Sales Footprint 17.3.6.4. Strategy Overview 17.3.7. Dr. Reddy’s Laboratories Ltd 17.3.7.1. Overview 17.3.7.2. Product Portfolio 17.3.7.3. Sales Footprint 17.3.7.4. Strategy Overview 17.3.8. Sun Pharmaceutical Industries Ltd. 17.3.8.1. Overview 17.3.8.2. Product Portfolio 17.3.8.3. Sales Footprint 17.3.8.4. Strategy Overview 18. Assumptions and Acronyms Used 19. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Huntington’s Disease Treatment Market Value (US$ Mn), By Treatment , 2015 – 2021
Table 2: Global Huntington’s Disease Treatment Market Value (US$ Mn), By Treatment , 2022 – 2032
Table 3: Global Huntington’s Disease Treatment Market, By Region, 2015 – 2021
Table 4: Global Huntington’s Disease Treatment Market, By Region, 2022 – 2032
Table 5: North America Huntington’s Disease Treatment Market Value (US$ Mn), By Treatment , 2015 – 2021
Table 6: North America Huntington’s Disease Treatment Market Value (US$ Mn), By Treatment , 2022 – 2032
Table 7: North America Huntington’s Disease Treatment Market, By Country, 2015 – 2021
Table 8: North America Huntington’s Disease Treatment Market, By Country, 2022 – 2032
Table 9: Latin America Huntington’s Disease Treatment Market Value (US$ Mn), By Treatment , 2015 – 2021
Table 10: Latin America Huntington’s Disease Treatment Market Value (US$ Mn), By Treatment , 2022 – 2032
Table 11: Latin America Huntington’s Disease Treatment Market, By Country, 2015 – 2021
Table 12: Latin America Huntington’s Disease Treatment Market, By Country, 2022 – 2032
Table 13: Europe Huntington’s Disease Treatment Market Value (US$ Mn), By Treatment , 2015 – 2021
Table 14: Europe Huntington’s Disease Treatment Market Value (US$ Mn), By Treatment , 2022 – 2032
Table 15: Europe Huntington’s Disease Treatment Market, By Country, 2015 – 2021
Table 16: Europe Huntington’s Disease Treatment Market, By Country, 2022 – 2032
Table 17: Asia Pacific Huntington’s Disease Treatment Market Value (US$ Mn), By Treatment , 2015 – 2021
Table 18: Asia Pacific Huntington’s Disease Treatment Market Value (US$ Mn), By Treatment , 2022 – 2032
Table 19: Asia Pacific Huntington’s Disease Treatment Market, By Country, 2015 – 2021
Table 20: Asia Pacific Huntington’s Disease Treatment Market, By Country, 2022 – 2032
Table 21: MEA Huntington’s Disease Treatment Market Value (US$ Mn), By Treatment , 2015 – 2021
Table 22: MEA Huntington’s Disease Treatment Market Value (US$ Mn), By Treatment , 2022 – 2032
Table 23: MEA Huntington’s Disease Treatment Market, By Country, 2015 – 2021
Table 24: MEA Huntington’s Disease Treatment Market, By Country, 2022 – 2032
Table 25: Global Huntington’s Disease Treatment Market Incremental $ Opportunity, By Treatment , 2015 - 2021
Table 26: Global Huntington’s Disease Treatment Market Incremental $ Opportunity, By Region, 2022 – 2032
Table 27: North America Huntington’s Disease Treatment Market Incremental $ Opportunity, By Treatment , 2015 - 2021
Table 28: North America Huntington’s Disease Treatment Market Incremental $ Opportunity, By Country, 2022 – 2032
Table 29: Latin America Huntington’s Disease Treatment Market Incremental $ Opportunity, By Treatment , 2015 - 2021
Table 30: Latin America Huntington’s Disease Treatment Market Incremental $ Opportunity, By Country, 2022 – 2032
Table 31: Europe Huntington’s Disease Treatment Market Incremental $ Opportunity, By Treatment , 2015 - 2021
Table 32: Europe Huntington’s Disease Treatment Market Incremental $ Opportunity, By Country, 2022 - 2032
Table 33: Asia Pacific Huntington’s Disease Treatment Market Incremental $ Opportunity, By Treatment , 2015 - 2021
Table 34: Asia Pacific Huntington’s Disease Treatment Market Incremental $ Opportunity, By Country, 2022 – 2032
Table 35: MEA Huntington’s Disease Treatment Market Incremental $ Opportunity, By Treatment , 2015 - 2021
Table 36: MEA Huntington’s Disease Treatment Market Incremental $ Opportunity, By Country, 2022 - 2032
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Huntington’s Disease Treatment Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032
Figure 2: Global Huntington’s Disease Treatment Market Absolute $ Historical Gain (2015 - 2021) and Opportunity (2022 – 2032), US$ Mn
Figure 3: Global Huntington’s Disease Treatment Market Share, By Treatment , 2022 & 2032
Figure 4: Global Huntington’s Disease Treatment Market Y-o-Y Growth Projections, By Treatment – 2022-2032
Figure 5: Global Huntington’s Disease Treatment Market Attractiveness Index, By Treatment – 2022-2032
Figure 6: Global Huntington’s Disease Treatment Market Share, By Region, 2022 & 2032
Figure 7: Global Huntington’s Disease Treatment Market Y-o-Y Growth Projections, By Region – 2022-2032
Figure 8: Global Huntington’s Disease Treatment Market Attractiveness Index, By Region – 2022-2032
Figure 9: North America Huntington’s Disease Treatment Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032
Figure 10: North America Huntington’s Disease Treatment Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032), US$ Mn
Figure 11: North America Huntington’s Disease Treatment Market Share, By Treatment , 2022 & 2032
Figure 12: North America Huntington’s Disease Treatment Market Y-o-Y Growth Projections, By Treatment – 2022-2032
Figure 13: North America Huntington’s Disease Treatment Market Attractiveness Index, By Treatment – 2022-2032
Figure 14: North America Huntington’s Disease Treatment Market Share, By Country, 2022 & 2032
Figure 15: North America Huntington’s Disease Treatment Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 16: North America Huntington’s Disease Treatment Market Attractiveness Index, By Country – 2022-2032
Figure 17: Latin America Huntington’s Disease Treatment Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032
Figure 18: Latin America Huntington’s Disease Treatment Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032), US$ Mn
Figure 19: Latin America Huntington’s Disease Treatment Market Share, By Treatment , 2022 & 2032
Figure 20: Latin America Huntington’s Disease Treatment Market Y-o-Y Growth Projections, By Treatment – 2022-2032
Figure 21: Latin America Huntington’s Disease Treatment Market Attractiveness Index, By Treatment – 2022-2032
Figure 22: Latin America Huntington’s Disease Treatment Market Share, By Country, 2022 & 2032
Figure 23: Latin America Huntington’s Disease Treatment Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 24: Latin America Huntington’s Disease Treatment Market Attractiveness Index, By Country – 2022-2032
Figure 25: Europe Huntington’s Disease Treatment Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032
Figure 26: Europe Huntington’s Disease Treatment Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032), US$ Mn
Figure 27: Europe Huntington’s Disease Treatment Market Share, By Treatment , 2022 & 2032
Figure 28: Europe Huntington’s Disease Treatment Market Y-o-Y Growth Projections, By Treatment – 2022-2032
Figure 29: Europe Huntington’s Disease Treatment Market Attractiveness Index, By Treatment – 2022-2032
Figure 30: Europe Huntington’s Disease Treatment Market Share, By Country, 2022 & 2032
Figure 31: Europe Huntington’s Disease Treatment Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 32: Europe Huntington’s Disease Treatment Market Attractiveness Index, By Country – 2022-2032
Figure 33: MEA Huntington’s Disease Treatment Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032
Figure 34: MEA Huntington’s Disease Treatment Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032), US$ Mn
Figure 35: MEA Huntington’s Disease Treatment Market Share, By Treatment , 2022 & 2032
Figure 36: MEA Huntington’s Disease Treatment Market Y-o-Y Growth Projections, By Treatment – 2022-2032
Figure 37: MEA Huntington’s Disease Treatment Market Attractiveness Index, By Treatment – 2022-2032
Figure 38: MEA Huntington’s Disease Treatment Market Share, By Country, 2022 & 2032
Figure 39: MEA Huntington’s Disease Treatment Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 40: MEA Huntington’s Disease Treatment Market Attractiveness Index, By Country – 2022-2032
Figure 41: Asia Pacific Huntington’s Disease Treatment Market Value (US$ Mn) and Year-on-Year Growth, 2015-2032
Figure 42: Asia Pacific Huntington’s Disease Treatment Market Absolute $ Opportunity Historical (2015 - 2021) and Forecast Period (2022 – 2032), US$ Mn
Figure 43: Asia Pacific Huntington’s Disease Treatment Market Share, By Treatment , 2022 & 2032
Figure 44: Asia Pacific Huntington’s Disease Treatment Market Y-o-Y Growth Projections, By Treatment – 2022-2032
Figure 45: Asia Pacific Huntington’s Disease Treatment Market Attractiveness Index, By Treatment – 2022-2032
Figure 46: Asia Pacific Huntington’s Disease Treatment Market Share, By Country, 2022 & 2032
Figure 47: Asia Pacific Huntington’s Disease Treatment Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 48: Asia Pacific Huntington’s Disease Treatment Market Attractiveness Index, By Country – 2022-2032
Figure 49: US Huntington’s Disease Treatment Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 50: US Huntington’s Disease Treatment Market Share, By Treatment , 2021
Figure 51: Canada Huntington’s Disease Treatment Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 52: Canada Huntington’s Disease Treatment Market Share, By Treatment , 2021
Figure 53: Brazil Huntington’s Disease Treatment Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 54: Brazil Huntington’s Disease Treatment Market Share, By Treatment , 2021
Figure 55: Mexico Huntington’s Disease Treatment Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 56: Mexico Huntington’s Disease Treatment Market Share, By Treatment , 2021
Figure 57: Germany Huntington’s Disease Treatment Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 58: Germany Huntington’s Disease Treatment Market Share, By Treatment , 2021
Figure 59: U.K. Huntington’s Disease Treatment Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 60: U.K. Huntington’s Disease Treatment Market Share, By Treatment , 2021
Figure 61: France Huntington’s Disease Treatment Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 62: France Huntington’s Disease Treatment Market Share, By Treatment , 2021
Figure 63: Italy Huntington’s Disease Treatment Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 64: Italy Huntington’s Disease Treatment Market Share, By Treatment , 2021
Figure 65: BENELUX Huntington’s Disease Treatment Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 66: BENELUX Huntington’s Disease Treatment Market Share, By Treatment , 2021
Figure 67: Nordic Countries Huntington’s Disease Treatment Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 68: Nordic Countries Huntington’s Disease Treatment Market Share, By Treatment , 2021
Figure 69: China Huntington’s Disease Treatment Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 70: China Huntington’s Disease Treatment Market Share, By Treatment , 2021
Figure 71: Japan Huntington’s Disease Treatment Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 72: Japan Huntington’s Disease Treatment Market Share, By Treatment , 2021
Figure 73: South Korea Huntington’s Disease Treatment Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 74: South Korea Huntington’s Disease Treatment Market Share, By Treatment , 2021
Figure 75: GCC Countries Huntington’s Disease Treatment Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 76: GCC Countries Huntington’s Disease Treatment Market Share, By Treatment , 2021
Figure 77: South Africa Huntington’s Disease Treatment Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 78: South Africa Huntington’s Disease Treatment Market Share, By Treatment , 2021
Figure 79: Turkey Huntington’s Disease Treatment Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 80: Turkey Huntington’s Disease Treatment Market Share, By Treatment , 2021
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
At what rate will the market for Huntington’s disease treatment expand until 2032?
As per Fact.MR, demand for Huntington’s disease treatment is forecast to register a CAGR of 20% from 2022 to 2032
What is the expected market value for Huntington’s disease treatment in 2032?
By 2032, the Huntington’s disease treatment industry revenue is expected to be valued at US$ 2.4 Billion
What is the growth outlook for Huntington’s disease treatment across North America?
Around 77% of all Huntingdon’s disease treatment is likely to be carried out across North America
How opportunistic will the industry likely be across the Asia-Pacific?
As of 2022, the Huntington’s disease treatment landscape in the Asia Pacific is likely to yield a revenue share of 45%
Which treatment category is expected to be dominant for Huntington’s disease?
Symptomatic treatment is likely to be the most preferred approach to Huntington’s disease, accumulating 98% revenue
What is the expected market worth for Huntington’s disease treatment in 2022?
By 2022-end, demand for Huntington’s disease treatment is forecast to reach US$ 432 Million
What was the market worth for Huntington’s disease treatment in 2021?
As of 2021, the Huntington’s disease treatment industry was valued at US$ 360 Million
At what CAGR did the market for Huntington’s disease treatment surge from 2015 to 2021?
From 2015-2021, the Huntington’s disease treatment market flourished at a CAGR of 15.6%,
Huntington’s Disease Treatment Market